Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,213,368
  • Shares Outstanding, K 173,102
  • Annual Sales, $ 916,710 K
  • Annual Income, $ -158,650 K
  • 60-Month Beta 1.41
  • Price/Sales 29.69
  • Price/Cash Flow N/A
  • Price/Book 15.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.64
  • Number of Estimates 9
  • High Estimate -0.29
  • Low Estimate -0.96
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
143.95 +10.47%
on 05/27/20
168.10 -5.40%
on 05/05/20
+13.38 (+9.19%)
since 05/01/20
3-Month
90.57 +75.58%
on 03/16/20
168.10 -5.40%
on 05/05/20
+45.16 (+39.66%)
since 02/28/20
52-Week
63.02 +152.33%
on 07/16/19
168.10 -5.40%
on 05/05/20
+93.95 (+144.38%)
since 05/31/19

Most Recent Stories

More News
Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SGEN : 159.02 (+1.15%)
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA(TM) (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer

--- Published Simultaneously in the Journal of Clinical Oncology and Presented in an Oral Session During the Virtual Scientific Program of the 2020 ASCO Annual Meeting -

SGEN : 159.02 (+1.15%)
Look for Shares of Seattle Genetics to Potentially Rebound after Yesterday's 2.79% Sell Off

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $143.95 to a high of $151.68. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of...

SGEN : 159.02 (+1.15%)
Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24, 2020

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology...

SGEN : 159.02 (+1.15%)
Merck's (MRK) Keytruda Successful in Several Cancer Studies

Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.

RHHBY : 43.4300 (+0.18%)
MRK : 79.56 (-1.44%)
BMY : 60.29 (+0.95%)
SGEN : 159.02 (+1.15%)
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

BMY : 60.29 (+0.95%)
SGEN : 159.02 (+1.15%)
MBRX : 1.1600 (+6.42%)
TAK : 19.21 (-1.49%)
Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners

Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.

REGN : 599.47 (-2.18%)
DXCM : 378.70 (+0.10%)
NFLX : 425.92 (+1.47%)
TSLA : 898.10 (+7.56%)
SGEN : 159.02 (+1.15%)
SPY : 305.55 (+0.40%)
QQQ : 234.06 (+0.30%)
JD : 54.73 (+0.74%)
MELI : 844.08 (-0.89%)
PYPL : 154.53 (-0.31%)
VTI : 154.75 (+0.68%)
IVV : 306.68 (+0.49%)
VOO : 280.97 (+0.44%)
ZM : 204.15 (+13.75%)
Seattle Genetics Announces ADCETRIS(R) (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the current conditional marketing...

TKPYY : 16.5900 (-0.90%)
SGEN : 159.02 (+1.15%)
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting

--- Additional Results for Recently FDA-Approved TUKYSA(TM) (tucatinib) to be Featured in Oral Presentation -

SGEN : 159.02 (+1.15%)
Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

IMMU : 33.42 (-0.51%)
SGEN : 159.02 (+1.15%)
ABBV : 90.70 (-2.13%)
RETA : 139.91 (-3.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 165.17
1st Resistance Point 162.10
Last Price 159.02
1st Support Level 156.07
2nd Support Level 153.11

See More

52-Week High 168.10
Last Price 159.02
Fibonacci 61.8% 127.96
Fibonacci 50% 115.56
Fibonacci 38.2% 103.16
52-Week Low 63.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar